Genomic Breast Cancer Test

Will chemotherapy help — or can it be safely avoided?

OncoBreast 21 looks at the genes inside your tumour to give a clear recurrence-risk score — so your breast cancer treatment can be personalised to you, and your oncologist can decide about chemotherapy with confidence.

A genomic test used alongside specialist care. It supports your oncologist's decision — it doesn't replace it.

Contact us
Hereditary Risk Germline BRCA1/2 & panel genes Expression Scoring 21-gene recurrence-risk score, 0–100 Pharmacogenomics Drug–gene safety & dosing One sample · three answers
Your Recurrence Score one clear result, 0 to 100
Lower riskHigher risk
Low — chemotherapy often unnecessary Medium — discuss with your oncologist High — chemotherapy likely to help
Breast cancer awareness — a woman wearing a pink ribbon
Interactive Journey

Your Care Journey Step-by-Step

From inherited risk through diagnosis, genomic prognosis, therapy and follow-up — here's how your care unfolds, with you at the centre and your oncologist guiding every step.

Know your inherited risk

A simple blood sample screens BRCA1, BRCA2, PALB2 and related hereditary-cancer genes — so you and your family understand risk early and can plan screening or prevention with your specialist.

BRCA1 · BRCA2 · PALB2 · CHEK2 · panel genes

Book a test
Prevention

Confirm the diagnosis, profile the tumour

Imaging, biopsy and ER / PR / HER2 status come together in one coordinated workup — giving your oncologist a clear picture of exactly which type of breast cancer is being treated.

Imaging · Biopsy · ER / PR / HER2 status

Book a test
Diagnosis

One clear recurrence-risk score

For ER-positive, HER2-negative early breast cancer, the 21-gene score places recurrence risk on a 0–100 scale — the evidence your oncologist needs to decide whether chemotherapy will truly help.

21-gene expression score · Low → High

Book a test
Prognosis Low High

The right drug, at the right dose

Pharmacogenomics checks genes like CYP2D6 (tamoxifen) and DPYD (fluoropyrimidines), so therapy is matched to how your body actually processes each medicine — improving benefit and avoiding harm.

CYP2D6 · DPYD · drug–gene dosing

Book a test
Treatment

Ongoing safety and follow-up

Every new prescription can be checked against your genomic profile to flag risky drug–gene interactions, while structured follow-up keeps surveillance on track long after treatment ends.

Interaction checks · structured surveillance

Book a test
Follow-up
What it means for you

A clearer answer about chemotherapy

For many people with ER-positive, HER2-negative early breast cancer, it isn't obvious whether chemotherapy is needed. OncoBreast 21 helps make that decision personal — based on your tumour, not averages.

Avoid what you don't need

Skip unnecessary chemotherapy

If your risk is low, you and your oncologist may safely choose to avoid chemotherapy and its side effects.

Personal to you

Based on your tumour's genes

Your result reflects your own cancer's biology — not a general rule applied to everyone.

Confidence in the plan

Support for your care team

Your oncologist uses the score alongside your other results to recommend the right treatment, with you.

How it works

Simple for you — no extra procedure

The test uses the tissue sample already taken during your biopsy or surgery. Here's the journey from sample to result.

Your existing sample

No new procedure is needed — the tumour tissue already collected in your care is used.

Genomic analysis

The laboratory measures the genes in your tumour that influence the chance of the cancer coming back.

Your clear score

You receive a single recurrence-risk score, placing your cancer in a lower-, medium- or higher-risk group.

Your oncologist guides care

Your specialist combines the score with your other results to recommend the right treatment, together with you.

Is it for me?

Who this test can help

OncoBreast 21 is designed for one specific situation. Your oncologist will confirm whether it's right for you.

✓ This test may be for you if

  • Your cancer is hormone-receptor positive (ER-positive)
  • It is HER2-negative
  • It is early-stage and invasive
  • It has spread to no lymph nodes, or only 1–3

✗ It isn't used for

  • HER2-positive breast cancer
  • Triple-negative breast cancer
  • Non-invasive changes (DCIS / LCIS only)
  • Advanced, inflammatory, or male breast cancer
Trusted science

Built on a genomic method used around the world

OncoBreast 21 uses the same kind of 21-gene genomic method that has informed breast-cancer treatment internationally for years, studied in large clinical trials. Our own validation in Indian patients is underway, and the result is designed to fit into the decisions you and your oncologist make together.

Established approach

A recognised method

It uses a well-studied way of reading tumour genes to estimate recurrence risk.

Specialist-led

Always with your oncologist

The result is a guide for your care team — your treatment decision always rests with your specialist.

For clinicians

Full evidence on request

Every report includes the clinical evidence and references your oncologist needs to interpret it.

What OncoBreast 21 is — and isn't

Honest about what this test does

We believe a test that informs your treatment should be described plainly. OncoBreast 21 gives a recurrence-risk score built on a well-established genomic method, plus an optional exploratory modelling layer that can illustrate how that risk might shift under different care options — it is not a diagnosis, and it does not make treatment decisions on its own.

It guides, it doesn't decide. Your oncologist makes the treatment decision, with you.
The score is grounded in established science. Your recurrence-risk score uses a genomic method studied in large clinical trials (TAILORx, RxPONDER); our own validation in Indian patients is underway.
Exploratory models — used carefully. Beyond the baseline score, an optional model can illustrate how risk paths might shift under different treatments. These projections enrich the clinical conversation but do not predict your outcome or replace your doctor's judgement.
Always improving. We are validating the test further in Indian patients, and every report is clear about its current status.
Free tool

Check your medicines for interactions

Add the medicines you take — including any breast-cancer treatment — and we'll check the official FDA drug labels for potential interactions between them. Free, no sign-up.

Common in breast-cancer care:
tamoxifenanastrozoleletrozoleexemestaneparoxetinewarfarin
Please read. This tool searches the official U.S. FDA drug-label text (via the public openFDA database) for whether one of your medicines is named in another's interaction section. It is informational only — not a diagnosis, not medical advice, and not a complete interaction check. It may miss interactions, and a result of "none found" does not mean a combination is safe. Always confirm with your oncologist or pharmacist before starting, stopping, or combining any medication.
Concerned about a result, or your treatment options? Talk to our team →
Free tool · Pharmacogenomics

Gene-based dosing check

If you have a pharmacogenomic (gene) test result, see how it affects medicines used in cancer care — based on CPIC and other international guidelines (FDA, DPWG), the standards for gene-guided prescribing. For discussion with your care team.

Please read. Based on CPIC and other international pharmacogenomic guidelines (CPIC, FDA, DPWG), each source noted with the result. This is educational decision-support, not a prescription or medical advice, and it assumes an accurate gene-test result. Genotype is only one factor; dosing must be decided by the treating oncologist. Always confirm with your care team.
Have a gene-test result and questions? Talk to our team →

Talk to us about OncoBreast 21

Ask your oncologist if this test is right for you, or get in touch to learn more.

Contact us